Andrea Wang-Gillam, Co-CEO at Jacobio Pharma, shared Jacobio Pharma’s post on LinkedIn, adding:
“The combination of KRAS G12 and SHP2 inhibitors continues to advance, offering hope for a potential chemotherapy-free front line option in NSCLC in the future!”
Jacobio Pharma shared a post on LinkedIn about a recent article by Jia Zhong et al. published in The Lancet Respiratory Medicine:
“We are pleased to share that clinical results from Jacobio’s all-oral KRAS G12C inhibitor glecirasib in combination with our SHP2 inhibitor JAB-3312 (sitneprotafib) have been published in The Lancet Respiratory Medicine (Impact Factor 32.8).
The Phase 1/2a study enrolled 171 patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) in China. In previously untreated patients (n=102), the combination achieved:
- 71% objective response rate
- 12.2 months median progression-free survival
These results represent one of the most robust first-line efficacy signals reported globally for a KRAS G12C + SHP2 inhibitor combination and underscore the potential of a chemotherapy-free, all-oral regimen.
Jacobio has initiated a Phase III clinical trial to further evaluate this combination in first-line KRAS G12C-mutated NSCLC. We remain committed to advancing innovative therapies that have the potential to benefit patients worldwide.”
Title: Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
Authors: Jia Zhong, Jun Zhao, Jianchun Duan, Jian Fang, Kailun Fei, Xiaoyan Li, Jiayan Chen, Zhijie Wang, Qian Chu, Yan Yu, Zhe Liu, Li Zhang, Yanqiu Zhao, Xingya Li, Lin Wu, Ligang Xing, Wu Zhuang, Xuefeng Fang, Jianhua Chang, Yueyin Pan, Xiaorong Dong, Lian Liu, Chunmei Bai, Pinhua Pan, Qibin Song, Bo Jin, Baoshan Cao, Feng Ye, Jianhua Shi, Kejing Tang, Andrea Wang-Gillam, Yuli Ding, Chao Bi, Yang Shao, Jiaohui Pang, Rui Wan, Boyang Sun, Jiachen Xu, Jie Wang
Read the Full Article on The Lancet Respiratory Medicine
More posts about Jacobio Pharma.